XPAR
CVX
Market cap141mUSD
Mar 02, Last price
3.20EUR
Name
Affluent Medical SAS
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Affluent Medical S.A., a French enterprise, specializes in the creation of minimally invasive medical solutions designed to address cardiovascular and vascular conditions. Its product pipeline includes the Kardiozis technology, engineered to manage abdominal aortic aneurysms, alongside the Kalios and Epygon implants, which target mitral insufficiency. Additionally, the company offers the Artus implant, an advanced electromechanical artificial sphincter devised for the comprehensive treatment of severe urinary incontinence in both female and male patients. Established in 2011, its headquarters are situated in Aix-en-Provence, France.
Key people
Michel Therin
Chairman of the Board · since 2023
Sebastien Ladet
Chief Executive Officer · since 2024
Christophe de Vregille
Chief Financial Officer · since 2023
Celine Buard
Marketing Director · since 2022
Claire Andre
Director of Quality Assurance
Olivier Bellamy
Director of Industrialization · since 2022
Eric Jague
Director of Regulatory Affairs
Francois Laborde
Chief Surgical Officer · since 2023
Marion Melot
Artus Program Director · since 2022
Laurent Miranda
Kalios Programme Director · since 2022
Benjamin Renault
Chief Development Officer · since 2023
Director, Representative of Truffle Capital · since 2018
Dominique Carouge
Independent Director · since 2020
Patrick Coulombier
Independent Director · since 2023
Soad El Ghazouani Achik
Independent Director · since 2021
Ellen Roche
Independent Director · since 2021
Liane Teplitsky
Independent Director · since 2025
Headquarters & legal address
900 RUE ANDRE AMPERE
BATIMENTS A ET C
AIX-EN-PROVENCE 13290
FR
BATIMENTS A ET C
AIX-EN-PROVENCE 13290
FR
Previous name
AFFLUENT MEDICAL
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||